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Chapter 1. General Introduction  
1.1 History of opioids  
Opium is a substance derived from the poppy (Papaver Somniferum), which has long been used for pain 
relief and to induce sleep.1 However, since opium has serious side effects including dependence, many 
researchers have attempted to separate these undesirable actions. In 1803, Sertürner isolated an alkaloid from 
opium and named it morphine (1)2 after Morpheus, the god of dreaming in Greek mythology (Figure 1). 
Various compounds exhibiting analgesic activity, including morphine (1), that were isolated from opium were 
collectively called “opiates”, which indicated that they were obtained from opium. In the mid-1970s, 
endogenous peptides exhibiting morphine-like effects were discovered, which did not originate from opium, 
and therefore “opiate” ceased to be recognized as an exact term. Currently, all compounds having a morphine-
like pharmacological action including endogenous peptides, synthetic drugs, and semi-synthetic drugs are 
known as “opioids”, meaning morphine-like substances. 
 
 
 
 
 
Figure 1. The structure of morphine (1) 
 
The structure of morphine (1) was proposed in 1925 by Gulland and Robinson3 and determined in 1927 by 
Schöpf et al.4 Although many researchers attempted to separate the analgesic effect from the drug dependence 
potential by chemically modifying morphine (1), these attempts were unsuccessful. Since two pentapeptide 
enkephalins (Met-enkephalin and Leu-enkephalin) were isolated from pig brain in 1976,5 over 20 types of 
endogenous opioid peptides including β-endorphin6, dynorphin7, and endomorphin8 were reported. Many such 
peptide derivatives were synthesized at that time, as these endogenous peptides were not expected to induce 
dependence. However, these attempts also failed, as even the endogenous peptides induced dependence. In 
1976, Martin et al. proposed three types of opioid receptors known as μ, , and σ.9 However, in a subsequent 
study, it was recognized that the σ receptor was different from opioid receptors, and the three receptors were 
alternatively named μ, , and δ (MOR, KOR, and DOR, respectively).10 In 1984, Portoghese et al. reported 
that mice pretreated with irreversible MOR antagonist β-FNA (2) showed analgesic effect without dependence 
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potential despite administration of morphine (1) (Figure 2).11 This result revealed that the morphine-like side 
effects typified by drug dependence were derived from MOR. Thus, DOR or KOR were expected to become 
targets for developing potent analgesics without dependence potential and many medicinal chemists began to 
develop DOR or KOR agonists. 
 
 
 
 
 
Figure 2. The structure of β-FNA (2) 
 
U-50488H (3) was reported as a highly selective non-peptidic KOR agonist developed by researchers at 
Upjohn Company (Figure 3).12 Subsequently, over 100 research groups worldwide continued to design and 
synthesize its derivatives to develop KOR agonists. As expected, these drugs showed high KOR selectivity 
and analgesic action without dependence potential; many pharmaceutical companies then conducted clinical 
trials of the U-50488H (3) derivatives. However, these compounds induced severe drug aversion 
(psychotomimetic effects such as visual and auditory hallucinations), which were opposite effects to drug 
dependence, and these U-50488H (3) derivatives were dropped in early clinical trials.13 However, in the early 
1990s, Nagase et al. focused on a partial structure, the N-terminal Tyr-Gly moiety in endogenous opioid 
peptides, designing and synthesizing nalfurafine (4) containing the Tyr-Gly moiety in a skeleton derived from 
naltrexone (5), which exhibited highly selective and potent KOR agonist activity (Figure 3).14 This was the 
first KOR agonist inducing neither drug dependence nor aversion, and the key to its success was the presence 
of a Tyr-Gly moiety in the agonist structure unlike other groups’ compounds. However, nalfurafine (4) was 
withdrawn from its application to post-operative pain, despite its strong analgesic effect. Nalfurafine (4) 
showed a strong sedative effect at the same dose as that for the analgesic effect in the clinical trials. Finally, 
nalfurafine (4) was released to the market for application to intractable pruritus in kidney dialysis patients in 
2009, and to severe itching in liver disease patients in 2015. 
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Figure 3. The structures of U-50488H (3), nalfurafine (4), naltrexone (5), and representative endogenous 
opioid peptides 
 
Nagase et al. employed the two concepts of “message–address”15 and “accessory site”16 in the design of 
nalfurafine (4). Portoghese et al. applied the “message–address concept” to synthesizing NTI (6)17 and nor-
BNI (7)18, which were selective non-peptidic opioid antagonists (Figure 4). In this concept, the “message” site 
is an essential structural moiety that binds with the receptor and exhibits activity, and the “address” site is a 
structural part involved in receptor selectivity. Moreover, the length of the “address” site determines the opioid 
receptor-type selectivity. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Message–address concept and the structures of MOR, DOR, and KOR-selective antagonists 
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The “accessory site” concept was based on the different structural features of the agonist and antagonist 
(Figure 5).16 Generally, after the agonist is bound to the target receptor, the receptor changes the shape to induce 
the effect. However, when the antagonist is bound to the receptor, the receptor does not change the shape but 
only disturbs the binding of the agonist. Additionally, the structures of the agonist tend to be smaller than those 
of the antagonist with additional lipophilic moieties. The additional lipophilic parts are termed “accessory 
sites”, which are usually hydrophobic and sterically bulky to hinder agonist binding. The antagonists could be 
designed by adding the “accessory sites” to the corresponding agonists, and the agonists could be designed by 
removing the “accessory sites” from the corresponding antagonists. 
 
 
 
 
 
 
 
 
Figure 5. Typical examples of structural differences between agonists and antagonists and the “accessory sites” 
 
Based on the “accessory site” concept, Nagase et al. synthesized the KOR agonist nalfurafine (4) by 
removing the lipophilic “accessory sites” from the KOR antagonist nor-BNI (7) (Figure 6).14 
 
 
 
 
 
 
 
Figure 6. Design of nalfurafine (4) by using the “accessory site” concept 
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The DOR agonist was also energetically developed worldwide with a focus on two leading compounds, 
SNC-80 (8)19 and TAN-67 (9)20 (Figure 7). SNC-80 (8) was developed by the National Institutes of Health, 
and TAN-67 (9) was developed by Nagase et al. Both compounds were expected to become analgesics without 
dependence potential. Although neither agonist appeared addicting, SNC-80 (8) induced strong convulsion and 
catalepsy in mice, and its development was ceased due to this side effect in early clinical trials. However, TAN-
67 (9) induced neither convulsions nor catalepsy, though its blood brain barrier permeation was insufficient. 
Subsequently, an improved ligand, KNT-127 (10)21 was designed and synthesized in 2010; this exhibited 
higher permeation through the blood brain barrier, and its DOR agonistic activity was 80 times more potent 
than TAN-67 (9) (Figure 7). Currently, a further improved derivative, NC-2800 is under development as an 
antidepressant and anxiolytic in a non-clinical study. 
 
 
 
 
 
 
 
Figure 7. The structures of representative DOR-selective agonists 
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1.2 Application studies on morphinan skeleton 
As described above, Nagase et al. focused on the morphinan skeleton, which possesses a useful Tyr-Gly 
partial structure at message sites for opioid receptors, and designed and synthesized several DOR and KOR-
selective ligands by using the commercially available naltrexone (5) as a starting material. Additionally, as 
opioid receptors showed various pharmacological activities including analgesic, the type-selective agonists 
were expected to form various useful drugs if their dependence potential was removed. During the studies, 
Nagase et al. also found that DOR antagonist BNTX (11) exhibited antiprotozoal activity,22 and nalfurafine (4) 
showed an antagonistic action against the orexin 1 receptor (OX1R) in recent years23 (Figure 8). By modifying 
the nalfurafine (4) structure, Nagase et al. synthesized the more potent and water soluble OX1R antagonist 
YNT-1310 (12),24 which attenuated withdrawal syndrome in morphine-dependent mice (Figure 8). As 
suggested by these studies, morphinan derivatives were expected to function not only as analgesics through 
opioid receptors but also as various drugs targeting for other receptors, and therefore Nagase et al. used the 
morphinan skeleton as a template for drug design and discovery. 
 
 
 
 
 
 
Figure 8. The structures of morphinan derivatives BNTX (11) and YNT-1310 (12) 
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As mentioned above, naltrexone (5) is a useful starting material and template; however, researchers 
sometimes encounter abnormal reactions originating from its characteristic 4,5-epoxy morphinan skeleton. 
Naltrexone (5) contains four sequential asymmetric centers and active functional groups including a 4,5-epoxy 
ring, two hydroxyl groups at the 3- and 14-positions, 17-basic nitrogen, and 6-ketone. As these functional 
groups are rigidly located on positions that can cause intramolecular interactions, this sometimes leads to 
unexpected and complex degradation products.25 For instance, acetylation of the 14-hydroxy group in 
naltrexone (5) with acetic anhydride/pyridine at room temperature yielded unusual triacetate 13 (Scheme 1).26 
The high tendency for enolization of the 6-ketone in naltrexone (5) activates the 7-axial hydrogen by the effects 
of neighboring group participation by the 17-basic nitrogen and 14-hydroxyl group, resulting in acetylation of 
the 14-hydroxy and 6-enolate groups shown in Scheme 1. By applying the abnormal enolization reaction, 
Nagase et al. readily synthesized the pyrrole, benzofuran, and indole rings in DOR and KOR antagonists 
including NTI (6),14 NTB (14),27 TRK-851 (15),28 and nor-BNI (7)18 in high yield (Figure 9). 
 
 
 
 
 
 
Scheme 1. The intramolecular interaction and acetylation of naltrexone (5) 
 
 
 
 
 
 
 
 
Figure 9. The structures of representative antagonists for DOR or KOR derived from naltrexone (5) 
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However, the 4,5-epoxy ring was extremely easily cleaved due to the strong ring strain, and the cleavage 
reactions were often encountered in reducing 6-ketone to the methylene group in synthesizing 
homogalanthamine (16).29 At Nagase laboratory, it was reported that many abnormal reactions were observed 
during the transformation of naltrexone (5), and these were controlled to afford novel compounds.25 Some 
examples of the conversion of naltrexone (5) are illustrated in Figure 10 (compounds 17 to 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Some examples of the novel compounds obtained by the abnormal reactions of naltrexone (5) 
 
Particularly, the conversion of naltrexone (5) into spiro compound 2130 was cited in the leading textbook on 
organic reaction mechanisms (The Art of Problem Solving in Organic Chemistry, second ed., 2014, Wiley), 
because product 21 was obtained via multiple steps and its structure was extremely complex as determined by 
2D NMR. When researchers have neither much experience nor knowledge of a number of specific abnormal 
reactions of the morphinan skeleton, they may encounter complex reaction products that cannot be isolated 
and whose structures are difficult to determine when naltrexone (5) is used as a template. Nagase et al. expected 
the reaction examples described in their previous papers, and this doctoral thesis will greatly assist researchers 
who utilize the morphinan skeleton for the first time.  
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Nagase et al. also synthesized natural physiologically active substances and their analogs, paying attention 
to common structural features between the morphinan skeleton and the natural products and attempting to 
convert naltrexone (5) to the natural products, mesembrane (23)31 and homogalanthamine (16),29 which 
possesses one extra carbon atom compared with the natural alkaloid galanthamine (24) (Figure 11). 
 
 
 
 
 
 
Figure 11. The structures of mesembrane (23), homogalanthamine (16), and galanthamine (24) 
 
Homogalanthamine (16) contains the same number of carbon atoms as naltrexone (5). Thus, Nagase et al. 
could synthesize homogalanthamine (16) from naltrexone via Grob fragmentation.32 In this reaction, the C9–
C14 bond was oriented antiperiplanar to the N17–Cl bond by the rigid morphinan skeleton (Scheme 2). In this 
synthesis, Nagase et al. also encountered many abnormal reactions derived from the morphinan skeleton. 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of homogalanthamine (16) from naltrexone (5) via Grob fragmentation 
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However, because the skeleton of galanthamine (24) contains one less carbon than that of naltrexone (5), 
one carbon atom must be removed from the morphinan skeleton to synthesize galanthamine (24). However, 
during the homogalanthamine (16) synthesis, Nagase et al. had no means to remove this carbon. Subsequently, 
they discovered a method for removing one carbon from the morphinan skeleton in their synthetic study on 
mesembrane (23).31 
Chapter 2 describes the synthesis of galanthamine (24) via a new synthetic route that removes one carbon 
from the morphinan skeleton.  
Chapter 3 describes a novel retro-ene reaction of an intermediate during the synthesis of mesembrane (23). 
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Chapter 2. Synthesis of Galanthamine from Naltrexone 
2.1 Background of galanthamine  
Galanthamine (24) is an alkaloid isolated from the Caucasian snowdrop plant (Galanthus woronowii), which 
belongs to the Amaryllidaceae family.33 Galanthamine (24) inhibits acetylcholinesterase and functions as a 
positive allosteric modulator of nicotinic acetylcholine receptors, consequently enhancing the effect of 
acetylcholine in the central nervous system.34 Thus, it has been clinically used to treat Alzheimer's disease in 
the US, EU, and Japan.35 
As described in the previous chapter, Nagase et al. successfully exploited the unique reactivity of the 
morphinan skeleton to develop various useful ligands and discovered many novel reactions unique to the 
skeleton. The author began the synthesis of galanthamine (24), which has a skeleton with one less carbon than 
naltrexone (5), by using the recently discovered method for removing one carbon from 5. 
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2.2 Retrosynthetic analysis of galanthamine 
Galanthamine (24) has three rings in common with naltrexone (5); these rings are termed A, C, and E-rings 
in naltrexone (5). Additionally, as mentioned above, 24 has one less carbon in its structure than naltrexone (5). 
Thus, the author attempted to synthesize galanthamine (24) by employing a C9 carbon removal method with 
seven-membered ring construction via C10–N17 bond formation (Figure 12).  
 
 
 
 
 
Figure 12. Common structure (green moieties) between naltrexone (5) and galanthamine (24) 
 
The retrosynthetic analysis of 24 was shown in Scheme 3. The seven-membered ring of 24 could be 
constructed by reductive amination of keto-aldehyde 25, which could be synthesized by the C9 carbon removal 
via oxidative cleavage of the vicinal diol moiety at the C9–C14 position in triol 26. Triol 26 was obtained by 
cleavage of the C9–C10 double bond via ozonolysis of allyl alcohol 27, which could be obtained from methyl 
ether 28 by Hofmann elimination of the C9–N17 bond. Compound 28 could be obtained from naltrexone (5) 
by employing the previously reported method.28  
 
 
 
 
 
 
 
 
 
 
Scheme 3. The retrosynthetic analysis of (−)-galanthamine (24) from naltrexone (5) 
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2.3 Synthesis of galanthamine 
The author attempted to reduce the ketone at the C6-position in naltrexone (5) to a methylene group. As 
previously reported for the synthesis of homogalanthamine (16), the direct reduction of the carbonyl group to 
a methylene group (Wolff–Kishner reduction,36 Clemmensen reduction, or thioacetal desulfurization using 
Raney nickel) led to cleavage of the 4,5-epoxy ring. Thus, in this synthesis, the author attempted to remove 
the ketone via the following multi-step process developed by Nagase’s group (Scheme 4).29  
Naltrexone hydrochloride (5·HCl) was converted to methyl ether 29 by methylating the phenolic hydroxy 
group. Diastereoselective reduction of the ketone in methyl ether 29 using NaBH(OAc)3 afforded alcohol 30, 
which was mesylated with MsCl to afford mesylate 31. A substitution reaction of the mesyl group in 31 with 
NaI, followed by treatment with DBU provided a mixture of olefins 32 and 33. As the 4,5-epoxy ring of olefin 
32 was also cleaved by hydrogenation using heterogeneous catalysts such as Pd/C and Pt2O,29 the author 
reduced the double bonds in the mixture of 32 and 33 with homogenous Wilkinson’s catalyst to afford 28. The 
high chemical reactivity of the 4,5-epoxy ring in the 4,5-epoxymorphinan skeleton appears to originate from 
the intrinsic strong ring strain derived from the A, B, C, and D-rings as well as the strong ring strain derived 
from the 4,5-epoxy ring. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Synthesis of 28 from 5·HCl  
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After methylating the basic nitrogen at the 17-position in 28, the C9–N17 bond in methiodide 34 was cleaved 
by Hofmann elimination to afford allyl alcohol 27 in high yield (Scheme 5). Acetylation of the tert-hydroxy 
group in 27 followed by decyclopropylmethylation with TrocCl gave acetate 35.37 The compound 35 was 
converted to dialdehyde 36 by ozonolysis and deprotection of the acetyl group to give dialdehyde-alcohol 37. 
The compound 37 was reduced with LiBH4 in MeOH to afford triol 26. Oxidative cleavage of the C9–C14 
bond in 26 with NaIO4 resulted in the C9 carbon removal. The benzyl alcohol of obtained keto-alcohol 38 was 
oxidized with MnO2 to afford keto-aldehyde 25. After acetalization of the ketone group of 25 by employing 
Kurihara's procedure,38 treating obtained aldehyde 39 with Zn in AcOH provided seven-membered compound 
40, possessing the basic skeleton of galanthamine (24). In this reaction, the Troc group was initially removed 
and the resulting sec-amine reacted with aldehyde to form iminium, which was subsequently reduced. The 
acetal group in 40 was deprotected to afford ketone 41. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5. Synthesis 41 from 28 via one-carbon removal 
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The author then examined the conversion of the ketone group in 41 to an α,β-unsaturated ketone group. 
However, after reacting 41 with PhSSPh, oxidation of the resulting phenyl sulfide 42 with m-CPBA produced 
undesired N-oxide 45, rather than sulfoxide 43 leading to α,β-unsaturated ketone 44 (Scheme 6). The 
susceptibility to oxidation of the basic nitrogen in 41 led to an attempt to protect the amino group with a Troc 
group. However, the attempt to protect the nitrogen led to keto-alcohol 38 which was the compound obtained 
four steps before and not target carbamate 47 (Scheme 7). The proposed reaction mechanism was shown in 
Scheme 7. In this way, as unexpected reactions often occur with the morphinan skeleton, researchers using 
morphinan derivatives should study the reactivity of the skeleton. 
 
 
 
 
 
 
 
 
 
 
Scheme 6. Examination of the selective sulfide oxidation in the presence of basic nitrogen 
 
 
 
 
 
 
 
 
 
Scheme 7. Unexpected seven-membered ring cleavage reaction of 41 to give 38 
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The author subsequently attempted to protect the basic nitrogen by protonation with acid. After examining 
several acids, desired phenyl sulfoxide 43 was successfully obtained by protonation of the nitrogen in 42 with 
CSA, followed by treatment with m-CPBA. Desired α,β-unsaturated ketone 44 was then obtained by treating 
43 with NaHCO3 under toluene reflux condition. The resulting 44 was reduced with NaBH4 in the presence of 
CeCl3·7H2O to afford allyl alcohols 49 and 50 in 58% and 28% yields, respectively. The stereochemistry of 
alcohol 49 was verified by X-ray crystallography (Figure 13). Finally, allyl alcohol 49 was converted to (−)-
galanthamine (24) and its diastereomer 51 in 48% and 23% yields by mesylation of the allyl alcohol and 
treatment with saturated aqueous NaHCO3 solution, as reported by Trost’s group39 (Scheme 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. Synthesis of (−)-galanthamine (24) 
 
 
 
 
 
 
Figure 13. ORTEP view of 49  
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2.4 Discovery of the effective one-carbon removal method 
In the above-mentioned synthesis of galanthamine (24), seven steps, including two oxidative cleavage 
reactions, were needed to remove the C9 carbon during the conversion of 27 to 25 (Scheme 9, (1)). The author 
attempted to find a more effective one-carbon removal method for synthesizing galanthamine (24) by focusing 
on the allyl alcohol structural moiety in 27. The author attempted to convert allyl alcohol 27 to triol 52 with 
OsO4 followed by oxidative cleavage of the triol with NaIO4 to remove the one carbon, but this reaction 
afforded only a complex mixture (Scheme 9, (2)).40 This result indicated that the basic nitrogen in 27 was 
oxidized under these conditions, leading to a complex mixture. Thus, protection of the basic nitrogen was 
attempted using acid. As expected, target keto-aldehyde 53 without the C9 carbon was obtained via Lemieux–
Johnson oxidation under acidic conditions with AcOH (Scheme 9, (3)). The resulting 53 was converted to 25 
with TrocCl. The five-step shorter alternative synthetic pathway was then completed to convert 27 to 25 in 
65% yield, compared to the previous route, which gave 57% yield. Obtained keto-aldehyde 25 was converted 
to galanthamine (24) in the same manner.  
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Scheme 9. Proposed synthetic pathway to 25 from 27  
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2.5 Conclusion 
In conclusion, the author synthesized galanthamine (24) from naltrexone (5) as a practical example of 
morphinan skeleton conversion with a focus on the common structure between the starting material and final 
product. During this synthesis, characteristic side reactions of the morphinan skeleton, such as cleavage of the 
4,5-epoxy ring and the seven-membered ring, were avoided. Hofmann elimination, two oxidative cleavages 
for the C9 carbon removal, and reductive amination to construct the seven-membered ring were the key 
reactions. Protonation of the basic nitrogen with acid was a useful protective method, which enabled Lemieux–
Johnson oxidation. This reaction saved five steps in the C9 carbon removal (Figure 14). The author hopes that 
the specific reactivity of the morphinan skeleton and the new carbon removal reaction reported in this thesis 
will be useful to medicinal chemists employing morphinan derivatives in the future. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Summary of the synthesis of galanthamine (24) from naltrexone hydrochloride (5·HCl) 
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Chapter 3. Novel Retro-Ene Reaction in Morphinan Derivatives 
3.1 Discovery of a novel retro-ene reaction 
During a study on synthesizing the biologically active natural product mesembrane (23) from naltrexone (5), 
acetylation of allyl alcohol 54 (acetic anhydride, 100 °C) afforded unexpected acetamides 56 and 57 in 55% 
and 26% yields, respectively, but not target acetylated product 55 (Scheme 10). The author was interested in 
this specific reaction of the morphinan skeleton and investigated the reaction mechanism. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. Discovery of abnormal amidation reaction of morphinan derivative 54 
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3.2 Studies of the scope of the reaction substrate and discovery of the key intermediate 
Initially, the author investigated whether the characteristic reaction occurred in the presence of the E-ring 
(4,5-epoxy ring) of the morphinan skeleton. The 4,5-epoxymorphinan derivative 59, corresponding to allyl 
alcohol 54 without the E-ring, was synthesized as follows. Based on a known procedure,41 naltrexone methyl 
ether (39) was acetalized to afford compound 58 in 90% yield; subsequently, Hofmann elimination of 58 
afforded target allyl alcohol derivative 59 in quantitative yield. Reaction of 4,5-epoxymorphinan derivative 59 
with acetic anhydride under the same conditions as for 54 afforded acetylation product 60 in 99% yield, unlike 
the reaction of morphinan derivative 54. The E-ring is known to play an important role in fixing the A-ring 
rotation to bind with the C-ring in morphinan derivatives.42 Thus, removal of the tert-acetate of 4,5-
epoxymorphinan 60 would be difficult because the E-ring fixed the conformation by preventing the 
A-ring rotation and disturbed the conjugation between the C9–C10 double bond and the A-ring. 
However, the A-ring in morphinan 55 can rotate to the position conjugating with the C9–C10 double bond, 
which could accelerate removal of the tert-acetate. 
 
 
 
 
 
 
 
 
 
 
Scheme 11. Synthesis of 4,5-epoxymorphinan 59 and its acetylation reaction 
 
Reaction substrate 54 with two types of alkyl side chains on the nitrogen atom afforded a mixture of products 
56 and 57. To facilitate elucidation of the reaction mechanism, the author prepared allyl alcohol derivative 63 
with an N,N-dimethylamino group. Initially, known Troc-protected compound 6121 was converted to N-methyl 
derivative 62 using LiAlH4 (Scheme 12). Hofmann elimination of 62 afforded target allyl alcohol derivative 
63. Allyl alcohol derivative 63 was expectedly converted into acetamide 56 with acetic anhydride as a single 
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product at 80 °C in 46% yield (method A) (Scheme 12). The reflux condition in acetic anhydride over 2 hours 
afforded desired compound 56 in 87% yield (method B). On the other hand, when the reaction was performed 
at 60 °C for 4 hours, followed by removal of acetic anhydride in vacuo (method C), a highly polar compound 
was mainly detected in the reaction system by TLC. The 1H NMR and 13C NMR spectra of the isolated polar 
product revealed two non-equivalent methyl groups (2.70 and 3.09 ppm) and downfield shifts of both protons 
at the C16 position and at the N-methyl groups (2.06, 2.53 → 3.77 ppm and 2.22 → 2.70, 3.09 ppm). Finally, 
1D and 2D NMR spectroscopy confirmed the compound to be quaternary ammonium salt 64 with a 
[4.4.3]propellane skeleton. Furthermore, obtained compound 64 was easily transformed into 56 in 81% yield 
from 63 under acetic anhydride reflux condition for 2 hours. These results confirmed that ammonium salt 64 
was the key intermediate in this unprecedented reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12. Reactions of morphinan 63 with the N,N-dimethylamino group and of isolated ammonium salt 
64 with acetic anhydride 
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3.3 Proposed reaction mechanism and verification experiment using a deuterated compound  
Based on these investigations, a proposed reaction mechanism was shown in Scheme 13. After acetylating 
the tert-allyl alcohol in 63 with acetic anhydride to afford acetate 65, the acetoxy group at the C14 position of 
65 was easily removed via the intramolecular nucleophilic electron-donating effect of the methoxy group at 
the C3 position to generate oxonium intermediate 66, followed by addition of the basic nitrogen at the 17-
position to the C14-position to afford quaternary ammonium salt 64. By a thermal retro-ene-type reaction, 
ammonium salt 64 was converted to iminium intermediate 67. Solvolysis of resulting iminium 67 afforded 
secondary amine 68, which was acetylated to afford acetamide 56. The lower reactivity of compound 63 with 
a dimethylamino group compared to compound 54 with cyclopropylmethylamino and methyl groups would 
originate from the higher electron donating ability of the cyclopropylmethyl group compared to that of the 
methyl group.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 13. Proposed reaction mechanism via quaternary ammonium salt intermediate 64  
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To confirm the proposed mechanism of the retro-ene reaction, the reaction was performed using N,N-
deuterated dimethylamino derivative 69 (Scheme 14). Deuterated substrate 69 was obtained from Troc-
protected compound 61 by employing the procedure for synthesizing allyl alcohol 63 (Scheme 12) with the 
corresponding deuterated reagents. Compound 61 was reduced with lithium aluminum deuteride to afford 
deuterated methyl amine 70 followed by Hofmann elimination using CD3I, which gave allyl alcohol 69. This 
was converted to acetamide 71, which was deuterated at the C10-position under reflux in acetic anhydride over 
4 hours, although the reaction of the deuterated 69 was relatively slow compared to that of 63.44 This result 
verified the proposed reaction mechanism described above. 
 
 
 
 
 
 
 
 
 
Scheme 14. Deuteration study to clarify the reaction mechanism 
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3.4 Conclusion 
In conclusion, the author discovered a novel retro-ene reaction of [4.4.3]propellane intermediate 64 
containing a quaternary ammonium linkage, which was achieved by nucleophilic addition of the basic nitrogen 
at the 17-position to the C14-position, and also confirmed the reaction mechanism by employing deuterated 
derivative 69 (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The mechanism of the novel retro-ene reaction via quaternary ammonium intermediate 64 
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Chapter 4. Conclusion 
In this doctoral thesis, the characteristic reactions of morphinan derivatives, which are useful for medicinal 
chemistry, were studied by employing commercially available naltrexone as a starting material. 
The first research topic addressed the C9 carbon removal of the morphinan skeleton and Lemieux–Johnson 
oxidation of 4,5-epoxymorphinan bearing a basic amino group under acidic condition. 
The second topic covers a novel retro-ene reaction via a [4.4.3]propellane skeleton intermediate containing 
a quaternary ammonium salt under acetic anhydride reflux condition. The author accidently discovered that 
reacting the morphinan derivative with acetic anhydride at 100 °C afforded unexpected acetoamides rather 
than simple acetylated morphinan during the synthesis of mesembrane from naltrexone. The reaction 
mechanism was clarified by using deuterated substrates and isolating the [4.4.3]propellane intermediate. 
Further experiments using the deuterated morphinan derivative clarified the mechanism by confirming 
rearrangement to the expected position of deuterium in the methyl group. 
This information should be useful to medicinal chemists interested in synthesizing bioactive morphinan 
alkaloids. 
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Experimental section 
General 
Thin layer chromatography (TLC) was performed on Merck Kieselgel 60 F254 plates (0.25 mm). Preparative 
TLC (PLC) was accomplished by using Merck Kieselgel 60 F254 plates (0.5 mm). Column chromatography 
was carried out on silica gel (spherical, neutral, 40–50 μm, Kanto Chemical Co.) or amino silica gel (60 μm, 
Fuji Silysia Chemical Ltd.). All melting points were determined on a Yanaco MP melting point (mp) apparatus 
and were uncorrected. Infrared spectra were recorded with a JASCO FT/IR 4100 spectrophotometer. 1H and 
13C NMR spectral data were obtained with JEOL JNM-ECS 400 instruments and an Agilent Technologies 
VXR-400NMR. Chemical shifts are quoted in ppm using tetramethylsilane (δ= 0 ppm) or CD3OD (δ = 3.31 
ppm) as the reference for 1H NMR spectroscopy, and CDCl3 (δ = 77.0 ppm) or CD3OD (δ = 49.0 ppm) or C6D6 
(δ = 128.0 ppm) for 13C NMR spectroscopy. High-resolution mass spectra were measured with a JEOL JMS-
T100LP spectrometer. Elemental analysis was performed with a YANACO CHN-CODER JM-10 model 
analyzer. The reactions were performed under an argon atmosphere unless otherwise noted. NH3 aq. is 28% 
aqueous ammonia solution. 
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(4R,4aS,7aS,12bS)-3-(Cyclopropylmethyl)-9-methoxy-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12-
methanobenzofuro[3,2-e]isoquinolin-4a-ol (28) 
 
 
 
 
 
Compound 28 was synthesized by a modified procedure of the reported method, and the spectral data were 
also reported.28 
A mixture of naltrexone hydrochloride (30.2 g, 79.9 mmol), K2CO3 (27.6 g, 200 mmol) and MeI (5.24 mL, 
83.9 mmol) in DMF (200 mL) was stirred at room temperature for 11 h, and additional MeI (0.2 mL, 3.20 
mmol) was added. The mixture was stirred for 13 h, and H2O (600 mL) was added. The mixture was extracted 
with Et2O (800, 300, 100, and 100 mL). The organic layer was washed with brine, and the aqueous layer was 
extracted with Et2O (100 mL). The combined organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. The crude product (28.8 g, white solid) was used in the next step without further purification. 
To a solution of the crude product (28.8 g) in AcOH (300 mL) was added NaBH(OAc)3 (25.4 g, 120 mmol), 
and the mixture was stirred at room temperature for 0.5 h. The reaction was quenched with acetone (50 mL). 
After being stirred for 2 h, the reaction mixture was concentrated under reduced pressure, and then 
azeotropically dried with toluene twice. To the residue was added H2O (100 mL), and basified with K2CO3 
(pH 9). The mixture was poured to H2O (150 mL) and extracted with CHCl3 (200, 100, and 50 mL). The 
organic layer was dried over Na2SO4 and concentrated under reduced pressure. The crude product (27.3 g, 
white solid) was used in the next step without further purification. To a solution of the crude product (27.3 g) 
in pyridine (200 mL) was added MsCl (12 mL, 155 mmol) at 0 °C, and the mixture was stirred for 0.5 h. The 
reaction mixture was poured to crushed ice and basified with K2CO3 (pH 9–10). The mixture was poured to 
H2O (300 mL) and extracted with CHCl3 (400, 200, 100, and 100 mL). The organic layer was washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure. The crude product (35.9 g, brown 
amorphous material) was used in the next step without further purification. A mixture of the crude product 
(35.9 g) and NaI (229.7 g, 1.53 mol) in DMF (300 mL) was stirred at 100 °C for 15 h. The hot reaction mixture 
was poured to H2O, basified with NaHCO3, and extracted with CHCl3 (600, 300, 150, and 100 mL). The 
organic layer was dried over Na2SO4, and concentrated under reduced pressure. The crude product (35.4 g, 
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brown solid) was used in the next step without further purification. A mixture of the crude product (35.4 g) 
and DBU (44.5 mL, 298 mmol) in DMF (300 mL) was stirred at 100 °C for 21 h. The reaction mixture was 
poured to saturated aqueous NaHCO3 solution (300 mL) / H2O (400 mL), and extracted with Et2O (400, 200, 
200, and 100 mL). The organic layer was washed with brine, dried over Na2SO4, and concentrated under 
reduced pressure. The crude product (30.6 g, brown amorphous material) was used in the next step without 
further purification. A mixture of the crude product (4.96 g) and RhCl(PPh3)3 (1.34 g, 1.45 mmol) in degassed 
benzene (80 mL) was stirred at room temperature for 40 h under a hydrogen atmosphere, and then concentrated 
under reduced pressure. The crude residue was purified by column chromatography on amino silica gel 
(EtOAc/n-hexane = 0/1→1/4), then silica gel (0→20%NH3 aq./MeOH/CPME = 1/9/90) in n-hexane) to afford 
compound 28 (4.01 g, 73% in 6 steps) as a brown oil.
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(4aS,4a1S,7aR)-4a1-{2-[(Cyclopropylmethyl)(methyl)amino]ethyl}-3-methoxy-4a,5,6,7-
tetrahydrophenanthro[4,5-bcd]furan-7a(4a1H)-ol (27) 
 
 
 
 
 
A mixture of compound 28 (1.0 g, 2.93 mmol) and MeI (10 mL, 161 mmol) in DMF (10 mL) was stirred at 
80 °C for 72 h, and additional MeI (3.0 mL, 48.2 mmol) was added. After being stirred for 24 h, the reaction 
mixture was concentrated under reduced pressure. The crude residue was dissolved in 1,4-dioxane (12 mL), 
and 1 M aqueous NaOH solution (12 mL) was added. The mixture was stirred at 80 °C for 2 h, and then poured 
to H2O (20 mL), and extracted with CHCl3 (50, 30, and 20 mL). The organic layer was dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel 
(0→2% (NH3 aq./MeOH = 1/9) in CHCl3) to afford compound 27 (1.03 g, 99%) as a colorless oil. 
 
IR (neat): 1505, 1282 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.08−0.18 (m, 2H), 0.48−0.59 (m, 2H), 0.82−0.93 (m, 1H), 1.21 (ddd, 
J = 13.6, 13.6, 2.8 Hz, 1H), 1.25−1.39 (m, 2H), 1.47−1.61 (m, 1H), 1.70−1.82 (m, 2H), 1.84–1.95 (m, 1H), 
2.15−2.32 (m, 4H), 2.34 (s, 3H), 2.41–2.51 (m, 1H), 3.87 (s, 3H), 4.78 (dd, J = 9.6, 8.0 Hz, 1H), 5.68 (d, J = 
9.2 Hz, 1H), 6.24 (d, J = 9.2 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 8.02 (br, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 3.8, 4.2, 8.4, 15.6, 29.6, 34.2, 36.3, 41.6, 50.3, 52.9, 56.1, 62.2, 73.7, 
92.0, 112.2, 117.2, 121.9, 124.1, 131.7, 140.4, 143.8, 145.2. 
HR-MS (ESI): m/z [M+H]+ calcd for C22H30NO3: 356.2226. Found: 356.2221.
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(4aS,4a1S,7aR)-3-Methoxy-4a1-(2-{methyl[(2,2,2-trichloroethoxy)carbonyl]amino}ethyl)-4a,5,6,7-
tetrahydrophenanthro[4,5-bcd]furan-7a(4a1H)-yl acetate (35) 
 
 
 
 
 
A solution of compound 27 (175 mg, 0.492 mmol) in Ac2O (1.0 mL) was stirred at 70 °C for 3 h. The 
reaction mixture was concentrated under reduced pressure, and the remained Ac2O was azeotropically removed 
with toluene. To a solution of the residue in CH2Cl2 (2.0 mL) was added Et3N (206 µL, 1.48 mmol) and 2,2,2-
trichloroethyl chloroformate (136 µL, 0.988 mmol) at 0 °C, and the mixture was stirred at room temperature 
for 0.5 h. To the mixture was added saturated aqueous NaHCO3 solution (5 mL), and the mixture was extracted 
with CHCl3 (15, 12, and 9 mL). The organic layer was dried over Na2SO4, and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel (EtOAc/n-hexane = 1/6 → 
2/1) to afford compound 35 (241 mg, 94%) as a colorless oil. 
 
IR (neat): 1720, 1507, 1244 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.19−1.43 (m, 4H), 1.93 (dt, J = 12.4, 5.2 Hz, 
0.4H), 2.02 (dt, J = 12.8, 4.8 Hz, 0.6H), 2.07−2.36 (m, 2H), 2.10 (s, 1.8H), 2.13 (s, 1.2H), 2.76−2.89 (m, 1.6H), 
2.81 (s, 1.2H), 2.83 (s, 1.8H), 3.11−3.30 (m, 0.8H), 3.55 (dt, J = 13.6, 4.4 Hz, 0.6H), 3.88 (s, 3H), 4.53 (d, J = 
12.0 Hz, 0.6H), 4.66 (d, J = 12.0 Hz, 0.4H), 4.72 (d, J = 12.0 Hz, 0.4H), 4.79 (d, J = 12.0 Hz, 0.6H), 4.89−4.97 
(m, 1H), 6.32 (d, J = 10.0 Hz, 1H), 6.46 (d, J = 10.0 Hz, 0.6H), 6.49 (d, J = 10.0 Hz, 0.4H), 6.63−6.74 (m, 2H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 15.3, 22.4, 29.5, 29.6, 30.1, 30.3, 31.6, 31.9, 33.9, 
34.9, 45.6, 46.2, 49.1, 56.0, 74.8, 87.5, 88.0, 90.2, 90.6, 95.5, 95.7, 112.66, 112.7, 118.1, 118.3, 122.7, 122.8, 
123.9, 124.0, 127.8, 128.2, 129.5, 129.7, 143.9, 145.2, 145.3, 154.0, 154.1, 169.8, 170.1. 
HR-MS (ESI): m/z [M+Na]+ calcd for C23H26Cl3NO6Na: 540.0723. Found: 540.0743. 
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(1S,4aS,9bS)-1,9-Diformyl-6-methoxy-9b-(2-{methyl[(2,2,2-trichloroethoxy)carbonyl]amino}ethyl)-
1,2,3,4,4a,9b-hexahydrodibenzo[b,d]furan-1-yl acetate (36) 
 
 
 
 
 
A solution of compound 35 (1.65 g, 3.18 mmol) in CH2Cl2 (400 mL) was stirred at −78 °C, and O3 was 
introduced for 8 min. The remained O3 was removed by sparging N2 for 20 min, and cold Me2S (−78 °C, 7.0 
mL, 95.3 mmol) was added. After sparging N2 for 20 min, the mixture was stirred at room temperature for 3 
h, and then concentrated under reduced pressure. The crude product was purified by column chromatography 
on silica gel (EtOAc/n-hexane, gradient) to afford compound 36 (1.59 g, 91%) as a colorless oil. 
 
IR (neat): 1722, 1688, 1282 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.39−1.54 (m, 1H), 1.68−2.42 (m, 7H), 2.21 (s, 
3H), 2.93 (s, 1.8H), 2.96 (s, 1.2H), 3.07−3.21 (m, 1H), 3.41−3.60 (m, 1H), 3.98 (s, 3H), 4.58 (d, J = 12.0 Hz, 
0.6H), 4.69 (d, J = 12.0 Hz, 0.4H), 4.75 (d, J = 12.0 Hz, 0.4H), 4.90−4.96 (m, 1H), 4.96 (d, J = 12.0 Hz, 0.6H), 
6.99 (d, J = 8.4 Hz, 0.4H), 7.00 (d, J = 8.4 Hz, 0.6H), 7.38 (d, J = 8.4 Hz, 1H), 9.56 (s, 1H), 9.67 (s, 0.6H), 
9.68 (s, 0.4H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 14.3, 14.4, 20.7, 20.8, 20.83, 21.2, 21.4, 28.7, 29.3, 
34.3, 35.2, 46.1, 46.5, 54.7, 54.73, 56.1, 75.0, 75.02, 87.8, 88.0, 88.5, 95.7, 111.2, 123.7, 124.0, 128.6, 128.7, 
131.9, 132.1, 150.2, 150.3, 153.8, 154.2, 169.8, 169.81, 191.7, 191.8, 197.0. 
HR-MS (ESI): m/z [M+Na]+ calcd for C23H26Cl3NO8Na: 572.0621. Found: 572.0635. 
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2,2,2-Trichloroethyl {2-[(5aS,9S,9aS)-1,9-diformyl-9-hydroxy-4-methoxy-6,7,8,9-
tetrahydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}(methyl)carbamate (37) 
 
 
 
 
 
A mixture of compound 36 (100 mg, 0.182 mmol) and Et3N (35 µL, 0.251 mmol) in MeOH (2.5 mL) was 
stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure, and purified 
by column chromatography on silica gel (EtOAc/n-hexane = 1/3 → 3/1) to afford compound 37 (93 mg, quant.) 
as a colorless oil. 
 
IR (neat): 3442, 1716, 1683, 1604, 1285 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.57−1.89 (m, 3H), 1.92–2.16 (m, 3H), 2.37–2.58 
(m, 1H), 2.72–3.02 (m, 2H), 2.92 (s, 1.8H), 2.96 (s, 1.2H), 3.39–3.63 (m, 1H), 3.98 (s, 1.8H), 3.99 (s, 1.2H), 
4.54–4.73 (m, J = 12.0 Hz, 2.4H), 4.85 (d, J = 12.0 Hz, 0.6H) 4.88–4.97 (m, 1H), 6.95 (d, J = 8.4 Hz, 0.4H), 
6.96 (d, J = 8.4 Hz, 0.6H), 7.48 (d, J = 8.4 Hz, 1H), 9.26 (s, 0.6H), 9.30 (s, 0.4H), 9.93 (s, 0.6H) 9.94 (s, 0.4H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 16.6, 16.9, 23.6, 23.64, 26.1, 26.9, 29.3, 29.6, 34.2, 
35.0, 45.8, 46.4, 53.6, 56.2, 75.0, 79.1, 79.2, 87.0, 87.1, 95.6, 111.4, 127.4, 128.8, 128.9, 129.2, 129.4, 148.8, 
148.9, 150.6, 150.63, 153.7, 154.1, 191.3, 191.4, 201.6, 201.8. 
HR-MS (ESI): m/z [M+Na]+ calcd for C21H24Cl3NO7Na: 530.0516. Found: 530.0531. 
.
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2,2,2-Trichloroethyl {2-[(5aS,9aS)-1-(hydroxymethyl)-4-methoxy-9-oxo-6,7,8,9-
tetrahydrodibenzo[b,d]furan-9a(5aH)-yl]ethyl}(methyl)carbamate (38) 
 
 
 
 
 
To a stirred solution of compound 37 (245 mg, 0.482 mmol) in MeOH (12 mL) was added LiBH4 (240 mg, 
11.0 mmol) at −40 °C. After additional 0.5 h, the reaction mixture was warmed to 0 °C, and then stirred for 
0.5 h. The reaction was quenched with saturated aqueous NaHCO3 solution (30 mL), and the mixture was 
extracted with CHCl3 (24, 18, and 12 mL). The organic layer was dried over Na2SO4, and concentrated under 
reduced pressure.  A mixture of the residue and NaIO4 (300 mg, 1.40 mmol) in DME/H2O (3/1) (16 mL) was 
stirred at room temperature for 12 h, and then H2O (6 mL) was added. The mixture was extracted with CH2Cl2 
(15, 12, and 7 mL). The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The 
crude product was purified by chromatography on silica gel (EtOAc/n-hexane = 1/3 → 3/1) to afford 
compound 38 (166 mg, 72%) as a colorless oil. 
 
IR (neat): 3466, 1711, 1507, 1280 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.74–1.89 (m, 2H), 1.97–2.13 (m, 2H), 2.20–2.31 
(m, 1H), 2.36–2.57 (m, 3H), 2.85–3.00 (m, 0.5H), 2.93 (s, 1.5H), 2.98 (s, 1.5H), 3.01–3.27 (m, 1H), 3.47–3.59 
(m, 0.5H), 3.90 (s, 3H), 4.43–4.74 (m, 3.5H), 4.84 (d, J = 12.0 Hz, 0.5H), 5.00–5.10 (m, 1H), 6.83 (d, J = 8.4 
Hz, 0.5H), 6.85 (d, J = 8.4 Hz, 0.5H), 6.89 (d, J = 8.4 Hz, 0.5H), 6.95 (d, J = 8.4 Hz, 0.5H). One proton (OH) 
was not observed. 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 17.5, 17.6, 28.1, 28.2, 31.3, 32.1, 34.4, 35.0, 38.0, 
38.2, 44.9, 45.7, 55.8, 60.7, 60.9, 61.2, 75.0, 88.0, 88.2, 95.4, 95.5, 112.3, 112.6, 123.0, 123.2, 125.1, 125.14, 
130.5, 131.0, 143.9, 144.2, 149.1, 153.9, 154.3, 211.2, 211.4. 
HR-MS (ESI): m/z [M+Na]+ calcd for C20H24Cl3NO6Na: 502.0567. Found: 502.0562. 
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2,2,2-Trichloroethyl {2-[(5aS,9aS)-1-formyl-4-methoxy-9-oxo-6,7,8,9-tetrahydrodibenzo[b,d]furan-9a(5aH)-
yl]ethyl}(methyl)carbamate (25) 
 
 
 
 
To a solution A mixture of compound 38 (150 mg, 0.312 mmol) and activated MnO2 (405 mg, 4.66 mmol) 
in 1,2-dichloroethane (5.0 mL) was stirred at 80 ° C for 12 h. The mixture was filtered through a pad of Celite, 
and the filtrate was concentrated under reduced pressure. The crude product was purified by chromatography 
on silica gel (EtOAc/n-hexane = 1/3 → 1/1) to afford compound 25 (138 mg, 92%) as a colorless oil. 
 
IR (neat): 1715, 1688, 1605, 1286 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.73–2.25 (m, 5H), 2.33–2.59 (m, 3H), 2.77–2.89 
(m, 1H), 2.91 (s, 1.8H), 2.94 (s, 1.2H), 3.38–3.51 (m, 1H), 3.995 (s, 1.2H), 4.00 (s, 1.8H), 4.56 (d, J = 12.0 
Hz, 0.6H), 4.66 (d, J = 12.0 Hz, 0.4H), 4.70 (d, J = 12.0 Hz, 0.4H), 4.79 (d, J = 12.0 Hz, 0.6H), 5.06–5.20 (m, 
1H), 6.98 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 0.6H), 7.49 (d, J = 8.4 Hz, 0.4H), 9.90 (s, 0.6H), 9.94 (s, 
0.4H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 18.3, 18.5, 28.2, 32.3, 32.8, 34.2, 35.0, 38.0, 44.9, 
45.4, 56.2, 60.9, 61.0, 74.96, 74.99, 90.0, 90.4, 95.5, 95.6, 111.6, 127.2, 127.3, 127.57, 127.6, 127.9, 149.3, 
149.4, 150.4, 153.8, 154.1, 189.8, 208.3, 208.6. 
HR-MS (ESI): m/z [M+Na]+ calcd for C20H22Cl3NO6Na: 500.0410. Found: 500.0412. 
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2,2,2-Trichloroethyl {2-[(4aS,9bS)-9-formyl-6-methoxy-2,3,4,4a-tetrahydro-9bH-spiro[dibenzo[b,d]furan-
1,2′-[1,3]dioxolane]-9b-yl]ethyl}(methyl)carbamate (39) 
 
 
 
 
 
A mixture of compound 25 (2.96 g, 6.18 mmol), ethylene glycol (1.8 mL, 32.3 mmol), 
isopropoxytrimethylsilane (17 mL, 95.7 mmol) and trimethylsilyl trifluoromethanesulfonate (570 µL, 3.15 
mmol) in 1,2-dichloroethane (60 mL) was stirred at 60 ° C for 6 h. The reaction mixture was poured to saturated 
aqueous NaHCO3 solution (70 mL), and extracted with CHCl3 (60 mL×2). The organic layer was dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was purified by column chromatography 
on silica gel (EtOAc/n-hexane = 1/2) to afford compound 39 (2.94 g, 91%) as a colorless oil. 
 
IR (neat): 1725, 1715, 1604, 1503 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) 1.51–1.78 (m, 3H), 1.88–2.06 (m, 3H), 2.20–2.42 
(m, 1H), 2.55–2.77 (m, 1H), 2.88–3.04 (m, 1H), 2.95 (s, 1.8H), 2.97 (s, 1.2H), 3.14 (dd, J = 14.8, 7.2 Hz, 0.4H), 
3.21 (dd, J = 14.8, 7.2 Hz, 0.6H), 3.42–3.62 (m, 1H), 3.69–3.93 (m, 3H), 3.95 (s, 3H), 4.64 (d, J = 12.0 Hz, 
0.6H), 4.70 (d, J = 12.0 Hz, 0.4H), 4.74 (d, J = 12.0 Hz, 0.4H), 4.78–4.91 (m, 1.6H), 6.90 (d, J = 8.4 Hz, 1H), 
7.53 (d, J = 8.4 Hz, 0.6H), 7.55 (d, J = 8.4 Hz, 0.4H), 10.25 (s, 0.6H), 10.28 (s, 0.4H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 17.0, 17.2, 23.4, 23.4, 28.9, 29.1, 29.7, 34.6, 35.2, 
46.2, 46.9, 55.9, 56.2, 56.2, 64.4, 64.5, 64.8, 75.1, 86.9, 87.0, 95.6, 95.6, 110.2, 111.2, 121.8, 122.0, 128.3, 
130.6, 131.0, 149.2, 149.8, 154.0, 154.2, 190.4, 190.7. 
HR-MS (ESI): m/z [M+Na]+ calcd for C22H26Cl3NO7Na: 544.0673. Found: 544.0661.  
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(4aS,8aS)-3-Methoxy-11-methyl-4a,5,6,7,9,10,11,12-octahydrospiro[benzo[2,3]benzofuro[4,3-cd]azepine-
8,2′-[1,3]dioxolane] (40) 
 
 
 
 
A mixture of compound 39 (921 mg, 1.76 mmol) and zinc powder (4.6 g, 70.3 mmol) in AcOH (15 mL) was 
stirred at room temperature for 22 h. The reaction mixture was filtered through a pad of Celite, and the filtrate 
was concentrated under reduced pressure. The residue was diluted with H2O (10 mL) and adjusted to pH 8 
with NH3 aq., and then extracted with CHCl3 (20, 10, 5, and 5 mL). The organic layer was washed with brine, 
dried over Na2SO4, and concentrated under reduced pressure. The crude residue was purified by 
chromatography on silica gel (1→7% (NH3 aq./MeOH = 1/9) in CHCl3) to afford compound 40 (420 mg, 72%) 
as a yellow oil. 
 
IR (neat): 1506, 1277 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.56–1.92 (m, 5H), 1.95–2.09 (m, 1H), 2.09–2.18 (m, 1H), 2.21–2.32 
(m, 1H), 2.29 (s, 3H), 2.77–2.91 (m, 1H), 3.09 (ddd, J = 7.6, 7.6, 7.6 Hz, 1H), 3.47 (d, J = 14.4 Hz, 1H), 3.47–
3.58 (m, 1H), 3.70–3.84 (m, 2H), 3.85 (s, 3H), 3.92 (ddd, J = 6.8, 6.8, 3.6 Hz, 1H), 4.40 (d, J = 14.4 Hz, 1H), 
4.40–4.46 (m, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H).  
13C NMR (100 MHz, CDCl3): δ (ppm) 18.0, 23.2, 29.3, 29.8, 41.3, 54.5, 54.7, 55.6, 59.4, 63.9, 64.2, 92.7, 
110.6, 112.3, 120.9, 130.2, 131.1, 143.6, 148.7.  
HR-MS (ESI): m/z [M+H]+ Calcd for C19H26NO4: 332.1862. Found: 332.1862. 
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(4aS,8aS)-3-Methoxy-11-methyl-4a,5,6,7,9,10,11,12-octahydro-8H-benzo[2,3]benzofuro[4,3-cd]azepin-8-
one (41) 
 
 
 
 
A mixture of compound 40 (229 mg, 0.690 mmol) and 2 M HCl (3.0 mL) in MeOH (3.0 mL) was stirred at 
60 °C for 12 h. The reaction mixture was adjusted to pH 10 with saturated aqueous NaHCO3 solution and 
K2CO3, and then extracted with CHCl3 (12, 6, 3, and 3 mL). The organic layer was dried over Na2SO4, and 
concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel 
(3→5% (NH3 aq./MeOH = 1/9) in CHCl3) to afford compound 41 (195 mg, 98%) as a colorless oil. 
 
IR (neat): 1706, 1508, 1271 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.88 (ddd, J = 14.4, 2.8, 2.8 Hz, 1H), 1.95–2.27 (m, 4H), 2.32–2.55 (m, 
3H), 2.35 (s, 3H), 2.97–3.07 (m, 2H), 3.57 (d, J = 14.8 Hz, 1H), 3.85 (s, 3H), 4.42 (d, J = 14.8 Hz, 1H), 4.69–
4.76 (m, 1H), 6.64 (d, J = 8.0 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 20.9, 25.9, 30.2, 38.4, 41.4, 53.8, 55.8, 61.0, 62.4, 91.7, 111.2, 121.6, 
129.9, 132.2, 143.4, 146.9, 211.3. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H22NO3: 288.1600. Found: 288.1599. 
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(4aS,8aS)-3-Methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-8H-benzo[2,3]benzofuro[4,3-cd]azepin-8-one 
(44) 
 
 
 
 
A solution of compound 41 (195 mg, 0.678 mmol) in THF (4.0 mL) was added to LDA solution [prepared 
from freshly distilled diisopropylamine (0.33 mL, 2.35 mmol) and n-BuLi (1.6 M in n-hexane, 1.27 mL, 2.03 
mmol) in THF (4.0 mL)] with stirring at −78 °C. After 0.5 h, a solution of diphenyl disulfide (740 mg, 3.39 
mmol) in THF (4.0 mL) was added at −78 °C, and then the mixture was stirred at 0 °C for 2 h. The reaction 
was quenched with H2O (10 mL), and the mixture was extracted with CHCl3 (20, 10, 5, and 5 mL). The organic 
layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel (CHCl3/n-hexane = 9/1, → [0.5→5% (NH3 aq./MeOH 
= 1/9) in CHCl3]) to afford a mixture of α- and β-phenylsulfide. A mixture of the phenylsulfide and (±)-
camphor-10-sulfonic acid (103 mg, 0.443 mmol) in CH2Cl2 (5.0 mL) was stirred at room temperature for 10 
min. A solution of m-CPBA (65%, 118 mg, 0.444 mmol) in CH2Cl2 (4.0 mL) was added at −78 °C, and the 
mixture was stirred at −40 °C for 0.5 h. The reaction was quenched with saturated aqueous Na2S2O3 solution 
(5 mL). The reaction mixture was poured to saturated aqueous NaHCO3 solution (10 mL), and then brine (10 
mL), and extracted with CHCl3 (20, 10, 5, and 3 mL). The organic layer was washed with brine, dried over 
Na2SO4, and concentrated under reduced pressure. A mixture of the crude residue and NaHCO3 (112 mg) in 
toluene (9.0 mL) was stirred at 110 °C for 2 h. After being cooled to room temperature, saturated aqueous 
NaHCO3 solution (10 mL) / H2O (10 mL) was added, and the mixture was extracted with CHCl3 (12, 6, 3, and 
3 mL). The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The crude residue 
was purified by column chromatography on silica gel (CHCl3/n-hexane = 9/1, → 0→3% (NH3 aq./MeOH = 
1/9) in CHCl3), and PLC ((NH3 aq./MeOH = 1/9):CHCl3 = 1:15) to afford compound 44 (79.6 mg, 41%) as a 
brown amorphous. 
 
IR (KBr): 1660, 1510, 1280 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.77 (ddd, J = 14.0, 3.6, 1.6 Hz, 1H), 2.11–2.24 (m, 1H), 2.41 (s, 3H), 
2.79 (dddd, J = 20.4, 5.2, 2.8, 2.8 Hz, 1H), 3.01 (ddd, J = 13.6, 2.8, 2.8 Hz, 1H), 3.11 (dd, J = 20.4, 5.6 Hz, 
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1H), 3.33–3.47 (m, 1H), 3.61 (d, J = 14.8 Hz, 1H), 3.83 (s, 3H), 4.71 (d, J = 14.8 Hz, 1H), 4.74–4.79 (m, 1H), 
6.12 (dd, J = 10.0, 1.6 Hz, 1H), 6.65 (d, J = 8.0 Hz, 1H), 6.68 (d, J = 8.0 Hz, 1H), 6.79–6.89 (m, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 26.2, 29.5, 41.3, 53.3, 55.8, 57.8, 60.7, 88.6, 111.3, 122.0, 129.5, 130.3, 
132.3, 143.2, 144.4, 146.8, 197.3. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H20NO3: 286.1443. Found: 286.1401.  
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(4aS,8R,8aR)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-8H-benzo[2,3]benzofuro[4,3-cd]azepin-8-ol 
(49) and (4aS,8S,8aR)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-8H-benzo[2,3]benzofuro[4,3- 
cd]azepin-8-ol (49) 
 
 
 
 
A mixture of compound 44 (79.6 mg, 0.277 mmol) and CeCl3·7H2O (314 mg, 0.842 mmol) in 
MeOH/CH2Cl2 (2.0 mL/1.0 mL) was stirred at room temperature for 10 min, and then NaBH4 (21.3 mg, 0.563 
mmol) was added at −78 °C. The reaction mixture was stirred at −40 °C for 1 h. The reaction was quenched 
with acetone (3 mL). The mixture was poured to aqueous NaHCO3 solution (10 mL) / H2O (10 mL), and 
extracted with CHCl3 (12, 6, 3, and 3 mL). The organic layer was washed with brine, and dried over Na2SO4, 
and concentrated under reduced pressure. The crude product was purified by PLC ((NH3 aq./MeOH = 
1/9):CHCl3 = 1:10) to afford compounds 49 (46.5 mg, 58%) as a colorless amorphous and 50 (22.5 mg, 28%) 
as a colorless oil. A portion of synthesized compound 49 was recrystallized from Et2O/n-hexane to give 
colorless prism crystals. 
 
Compound 49  
mp 163–165 °C. 
IR (KBr): 3422, 1510, 1282 cm-1. 
1H NMR (400 MHz, CD3OD): δ (ppm) 1.63–1.91 (m, 1H), 2.00–2.11 (m, 1H), 2.29–2.48 (m, 1H), 2.35 (s, 
3H), 2.75 (ddd, J = 17.6, 5.6, 2.8 Hz, 1H), 2.84–3.05 (m, 1H), 3.24–3.45 (m, 1H), 3.52 (d, J = 14.4 Hz, 1H), 
3.78 (s, 3H), 4.20–4.46 (m, 2H), 4.57–4.64 (m, 1H), 5.76–5.85 (m, 1H), 5.88–5.96 (m, 1H), 6.59 (d, J = 8.4 
Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H). One proton (OH) was not observed. 
13C NMR (100 MHz, CD3OD): δ (ppm) 27.4, 36.6, 42.7, 49.7, 55.1, 56.6, 62.1, 70.0, 90.0, 113.0, 122.6, 125.8, 
131.7, 132.7, 133.4, 144.9, 149.8. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H22NO3: 288.1600. Found: 288.1594.  
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Compound 50 
IR (neat): 3356, 1506, 1280 cm-1. 
1H NMR (400 MHz, CD3OD): δ (ppm) 1.70–1.88 (m, 1H), 2.18 (ddd, J = 14.4, 5.6, 2.8 Hz, 1H), 2.34 (s, 3H), 
2.53–2.61 (m, 1H), 2.63–2.73 (m, 1H), 2.83–2.95 (m, 1H), 3.25–3.42 (m, 1H), 3.59 (d, J = 14.8 Hz, 1H), 3.79 
(s, 3H), 4.26 (d, J = 14.8 Hz, 1H), 4.29–4.39 (m, 1H), 4.52 (dd, J = 4.8, 1.6 Hz, 1H), 5.82–5.92 (m, 1H), 5.94–
6.04 (m, 1H), 6.60 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H). One proton (OH) was not observed. 
13C NMR (100 MHz, CD3OD): δ (ppm) 27.9, 31.7, 43.2, 53.8, 56.2, 56.6, 61.1, 69.0, 90.9, 113.0, 122.5, 128.0, 
129.3, 133.0, 135.1, 145.0, 149.4. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H22NO3: 288.1600. Found: 288.1600.
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(–)-Galanthamine (24) and epi-galanthamine (51) 
 
 
 
 
 
To a solution of compound 24 (69 mg, 0.240 mmol) in CH2Cl2 (5.0 mL) were added Et3N (170 µL, 1.22 
mmol) and MsCl (60 µL, 0.775 mmol) at 0 °C. The mixture was stirred at the same temperature for 0.5 h, and 
then saturated aqueous NaHCO3 solution (15 mL) was added. The reaction mixture was stirred at room 
temperature for 1.5 h, and then extracted with CHCl3 (30, 20, and 10 mL). The organic layer was dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was purified by PLC ((NH3 aq./MeOH 
= 1/9):CHCl3 = 2:25) to afford (−)-galanthamine (24) (33.1 mg, 48%) as a colorless solid and compound 51 
(15.7 mg, 23%) as a colorless amorphous. A portion of synthesized (−)-galanthamine (24) was recrystallized 
from EtOAc/n-hexane to give light yellow needle crystals. 
 
(−)-Galanthamine (24) 
mp 128–130 °C (lit.45; mp 128–129 °C). 
[α]D20 −89.7 (c = 0.6, CHCl3) (lit.45; [α] D20 −93.4 (c = 1, CHCl3)).  
IR (KBr): 3549, 3376, 1507, 1282 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.51–1.64 (m, 1H), 2.01 (ddd, J = 16.0, 4.8, 2.8 Hz, 1H), 2.09 (ddd, J = 
13.2, 13.2, 2.8 Hz, 1H), 2.40 (s, 3H), 2.50 (brs, 1H), 2.62–2.75 (m, 1H), 2.98–3.14 (m, 1H), 3.19–3.33 (m, 1H), 
3.68 (d, J = 15.2 Hz, 1H), 3.83 (s, 3H), 4.09 (d, J = 15.2 Hz, 1H), 4.14 (dd, J = 4.8, 4.8 Hz, 1H), 4.56–4.66 (m, 
1H), 6.00 (dd, J = 10.0, 4.8 Hz, 1H), 6.07 (d, J = 10.0 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 8.4 Hz, 
1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 29.9, 33.7, 42.0, 48.1, 53.8, 55.8, 60.6, 62.0, 88.7, 111.0, 122.0, 126.8, 
127.5, 129.3, 132.9, 144.0, 145.7. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H22NO3: 288.1600. Found: 288.1595. 
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Compound 51 
IR (film): 3323, 1506, 1278 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.65 (ddd, J = 13.6, 13.6, 1.6 Hz, 1H), 1.72 (ddd, J = 13.6, 10.4, 2.4 Hz, 
1H), 2.19 (ddd, J = 13.2, 13.2, 3.2 Hz, 1H), 2.38 (s, 3H), 2.79 (dddd, J = 14.0, 5.6, 4.0, 1.6 Hz, 1H), 2.99–3.12 
(m, 1H), 3.20–3.33 (m, 1H), 3.63 (d, J = 15.2 Hz, 1H), 3.84 (s, 3H), 4.07 (d, J = 15.2 Hz, 1H), 4.56–4.71 (m, 
2H), 5.77–5.86 (m, 1H), 6.08 (ddd, J = 10.8, 1.6, 1.6 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 8.0 Hz, 
1H). One proton (OH) was not observed. 
13C NMR (100 MHz, CDCl3): δ (ppm) 32.4, 34.3, 42.1, 48.1, 54.0, 55.8, 60.4, 63.3, 88.4, 110.8, 121.5, 126.6, 
129.2, 131.5, 132.9, 143.8, 146.6. 
HR-MS (ESI): m/z [M+H]+ calcd for C17H22NO3: 288.1600. Found: 288.1590.
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(5aS,9aS)-9a-{2-[(Cyclopropylmethyl)(methyl)amino]ethyl}-4-methoxy-9-oxo-5a,6,7,8,9,9a-
hexahydrodibenzo[b,d]furan-1-carbaldehyde (53) 
 
 
 
 
 
To a stirred solution of compound 27 (19.8 mg, 55.7 mmol) in acetone/AcOH (2.0 mL/0.2 mL) were added 
NaIO4 (60.3 mg, 0.282 mmol) in H2O (2.0 mL) and OsO4 in t-BuOH (2 mg/mL, 0.72 mL, 5.66 mmol), and the 
mixture was stirred at room temperature for 60 h. The reaction was quenched with saturated aqueous Na2S2O3 
solution (10 mL) / saturated aqueous NaHCO3 solution (15 mL), and the mixture was extracted with CHCl3 
(20, 10, and 5 mL). The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The 
crude product was purified by PLC ((NH3 aq./MeOH = 1/9):CHCl3 = 1:20) to afford compound 53 (16.0 mg, 
80%) as a brown oil.  
 
IR (neat): 1706, 1684, 1604, 1286 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) (−0.03)–0.10 (m, 2H), 0.39–0.51 (m, 2H), 0.69–0.81 (m, 1H), 1.81–2.36 
(m, 9H), 2.24 (s, 3H), 2.37–2.56 (m, 3H), 3.98 (s, 3H), 5.09–5.14 (m, 1H), 6.93 (d, J = 8.8 Hz, 1H), 7.53 (d, J 
= 8.8 Hz, 1H), 10.08 (s, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 4.6 (×2), 6.4, 18.7, 28.0, 30.0, 38.1, 40.3, 51.9, 56.3, 61.0, 61.3, 90.4, 
112.0, 126.9, 127.1, 128.6, 149.9, 150.5, 190.8, 208.5. 
HR-MS (ESI): m/z [M+H]+ calcd for C21H28NO4: 358.2018. Found: 358.2015. 
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2,2,2-Trichloroethyl {2-[(5aS,9aS)-1-formyl-4-methoxy-9-oxo-6,7,8,9-tetrahydrodibenzo[b,d]furan-9a(5aH)-
yl]ethyl}(methyl)carbamate (25) 
 
A mixture of compound 53 (12.5 mg, 34.5 mmol), (i-Pr)2NEt (18.3 µL, 0.105 mmol) and 2,2,2-trichloriethyl 
chloroformate (5.8 µL, 42.1 µmol) in 1,2-dichloroethane (1.0 mL) was stirred at room temperature for 6 h, and 
then additional (i-Pr)2NEt (18.3 µL, 0.105 mmol) and 2,2,2-trichloroethyl chloroformate (5.8 µL, 42.1 µmol) 
were added. After 13 h, additional (i-Pr)2NEt (36.5 µL, 0.210 mmol) and 2,2,2-trichloroethyl chloroformate 
(11.5 µL, 83.5 µmol) were added. After 3 h, (i-Pr)2NEt (18.3 µL, 0.105 mmol) was added. The mixture was 
stirred for 2 h, and then poured to saturated aqueous NaHCO3 solution (5 mL), and extracted with CHCl3 (5, 
3, and 2 mL). The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The crude 
product was purified by PLC (EtOAc:n-hexane = 1:1) to afford compound 25 (13.6 mg, 81%) as a colorless 
oil. 
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(4aR,10aR)-4a-{2-[(Cyclopropylmethyl)(methyl)amino]ethyl}-6-methoxy-1,2,4,4a-tetrahydro-10aH-
spiro[phenanthrene-3,2′-[1,3]dioxolan]-10a-ol (54) 
 
 
 
 
 
A mixture of compound 7246 (0.401g, 1.04 mmol) and MeI (2.5 mL, 40.2 mmol) in DMF (2.5 mL) was 
stirred at 80 °C in a sealed tube for 12 h. The reaction mixture was cooled to room temperature, and 
concentrated under reduced pressure. The crude residue was dissolved in 1,4-dioxane (5.0 mL), and 1 M 
aqueous NaOH solution (5.0 mL, 5.00 mmol) was added. After being stirred at 80 °C for 17 h, and the mixture 
was extracted with CHCl3 (20, 15, and 5 mL). The organic layer was dried over Na2SO4, and concentrated 
under reduced pressure. The crude product was purified by column chromatography on silica gel (0→10% 
(NH3 aq./MeOH = 1/9) in CHCl3) to afford compound 54 (406 mg, 98%) as a colorless oil. 
 
IR (neat): 3401, 1606, 1275 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.06–0.20 (m, 2H), 0.47–0.61 (m, 2H), 0.83–0.95 (m, 1H), 1.28–1.45 
(m, 1H), 1.48–1.58 (m, 1H), 1.58–1.73 (m, 2H), 1.98–2.24 (m, 5H), 2.24–2.42 (m, 2H), 2.30 (s, 3H), 2.66 (dd, 
J = 12.1, 12.1 Hz, 1H), 3.80 (s, 3H), 3.75–4.02 (m, 4H), 5.78 (d, J = 9.6 Hz, 1H), 6.30 (d, J = 9.6 Hz, 1H), 
6.68 (dd, J = 8.2, 2.8 Hz, 1H), 6.94 (d, J = 2.8 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H). One proton (OH) was not 
observed. 
13C NMR (100 MHz, CDCl3): δ (ppm) 3.8, 4.2, 8.0, 30.3, 32.5, 36.3, 36.9, 40.7, 48.1, 52.3, 55.2, 61.7, 63.7, 
64.3, 71.1, 109.4, 110.1, 113.2, 124.9, 125.4, 128.0, 136.0, 144.9, 158.3. 
HR-MS (ESI): m/z [M+H]+ calcd for C24H34NO4: 400.2488. Found: 400.2470. 
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(S)-N-{2-[6-Methoxy-1,9-dihydro-2H-spiro[phenanthrene-3,2′-[1,3]dioxolan]-4a(4H)-yl]ethyl}-N-
methylacetamide (56) and (S)-N-(cyclopropylmethyl)-N-{2-[6-methoxy-1,9-dihydro-2H-spiro[phenanthrene-
3,2′-[1,3]dioxolan]-4a(4H)-yl]ethyl}acetamide (57) 
 
 
 
 
 
1) Retro-ene reaction of compound 54 
A solution of compound 54 (0.10 g, 0.250 mmol) in Ac2O (2.6 mL) was stirred at 100 °C for 3 h, then cooled 
to room temperateure, and concentrated under reduced pressure. The crude product was purified by PLC (n-
hexane:THF = 1:1) to afford compounds 56 (51.0 mg, 55%) as a colorless oil and 57 (26.8 mg, 26%) as a 
colorless oil. 
 
2) Retro-ene reaction of compound 63 
A solution of compound 63 (50.7 mg, 0.140 mmol) in Ac2O (2.0 mL, 21.2 mmol) was stirred under reflux 
for 2 h, then cooled to room temperature, and concentrated under reduced pressure. The crude product was 
purified by PLC (n-hexane:THF= 3:2, twice) to afford compound 56 (45.5 mg, 87%) as a colorless oil. 
 
Compound 56 
IR (neat): 1644, 1504, 1274 cm-1. 
1H NMR (400 MHz, C6D6, mixture of rotamers): δ (ppm) 1.51–1.77 (m, 1.4H), 1.54 (s, 1.2H), 1.66 (s, 1.8H) , 
1.78–1.91 (m, 1H), 1.92–2.13 (m, 2H), 2.17 (ddd, J = 13.7, 4.4, 2.5 Hz, 0.4H), 2.36 (dd, J = 13.7, 2.3 Hz, 
0.6H), 2.42–2.58 (m, 2H), 2.65–2.77 (m, 0.6H), 2.67 (s, 1.8H), 2.81–3.08 (m, 1H), 3.03 (ddd, J = 13.3, 11.9, 
4.6 Hz, 0.4H), 3.08–3.30 (m, 2H), 3.25–3.72 (m, 4.6H), 3.33 (s, 1.8H), 3.41 (s, 1.2H), 5.50–5.55 (m, 0.6H), 
5.61–5.65 (m, 0.4H), 6.66–6.76 (m, 1H), 6.81–6.91 (m, 1.6H), 7.06 (d, J = 2.3 Hz, 0.4H). 
13C NMR (100 MHz, C6D6, mixture of rotamers): δ (ppm) 20.6, 21.5, 29.5, 29.6, 30.3, 30.4, 32.9, 35.3, 36.2, 
36.3, 36.8, 38.1, 41.5, 41.8, 44.5, 47.2, 48.5, 49.2, 54.8, 63.6, 63.8, 64.9, 64.9, 109.0, 109.3, 110.5, 110.9, 
112.4, 112.7, 120.4, 120.7, 125.2, 125.6, 129.2, 129.3, 136.5, 137.1, 142.6, 143.1, 159.1, 159.2, 168.8, 168.9. 
HR-MS (ESI): m/z [M+Na]+ calcd for C22H29NO4Na: 394.1994. Found: 394.1978. 
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Compound 57 
IR (neat): 1643, 1504, 1272 cm-1. 
1H NMR (400 MHz, CDCl3, mixture of rotamers): δ (ppm) (–0.24)– 0.10 (m, 2H), 0.28–0.45 (m, 2H), 0.61–
0.81 (m, 1H), 1.55 (ddd, J = 14.0, 13.1, 4.6 Hz, 1H), 1.65–1.94 (m, 3.4H), 1.81 (s, 1.8H), 2.01 (s, 1.2H), 2.22–
2.36 (m, 2H), 2.41–2.59 (m, 1H), 2.59–2. 90 (m, 2.4H), 2.92– 3.05 (m, 1.6H), 3.15 (dd, J = 14.0, 6.6 Hz, 0.6H), 
3.28–3.39 (m, 2H), 3.87–4.12 (m, 4H), 3.787 (s, 1.8H), 3.793 (s, 1.2H), 5.77–5.85 (m, 1H), 6.71–6.85 (m, 2H), 
7.00 (d, J = 8.5 Hz, 0.4H), 7.03 (d, J = 8.5 Hz, 0.6H). 
13C NMR (100 MHz, CDCl3, mixture of rotamers): δ (ppm) 3.2, 3.3, 3.5, 3.6, 9.6, 10.1, 20.9, 21.7, 29.2, 29.9, 
30.0, 35.6, 36.6, 38.2, 41.2, 41.4, 42.2, 44.6, 47.5, 48.0, 49.3, 52.9, 55.3, 63.6, 63.8, 64.8, 108.8, 109.0, 110.2, 
110.4, 112.1, 112.3, 120.0, 120.6, 125.2, 125.4, 128.8, 129.0, 135.8, 136.5, 142.0, 142.5, 158.3, 158.4, 169.5, 
170.2. 
HR-MS (ESI): m/z [M+Na]+ calcd for C25H33NO4Na: 434.2307. Found: 434.2297. 
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(3aR,3a1S,9aR)-3a1-{2-[(Cyclopropylmethyl)(methyl)amino]ethyl}-5-methoxy-1,2,3a,3a1-tetrahydro-9aH-
spiro[phenanthro[4,5-bcd]furan-3,2′-[1,3]dioxolan]-9a-ol (59)  
 
 
 
 
 
A mixture of compound 7341 (0.302 g, 0.760 mmol) and MeI (2.0 mL, 32.1 mmol) in DMF (2.0 mL) was 
stirred at 80 °C in a sealed tube for 18 h. The reaction mixture was cooled to room temperature, and 
concentrated under reduced pressure. The crude residue was dissolved in 1,4-dioxane (3.0 mL), and 1 M 
aqueous NaOH solution (3.0 mL, 3.00 mmol) was added. The mixture was stirred at 80 °C for 4 h, then cooled 
to room temperature, and extracted with CHCl3 (20, 10, and 5 mL). The organic layer was dried over Na2SO4, 
and concentrated under reduced pressure. The crude product was purified by column chromatography on silica 
gel (0→10% (NH3 aq./MeOH=1/9) in CHCl3) to afford compound 59 (326 mg, 100%) as a colorless solid.  
 
mp: 129.8–131.1 °C. 
IR (KBr): 3421, 1501, 1269 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 0.08–0.20 (m, 2H), 0.49–0.59 (m, 2H), 0.81–0.94 (m, 1H), 1.43 (ddd, J 
= 13.3, 3.9, 2.5 Hz, 1H), 1.61 (ddd, J = 14.0, 14.0, 2.3 Hz, 1H), 1.68–1.84 (m, 2H), 1.89–2.04 (m, 2H), 2.22 
(dd, J = 13.5, 7.6 Hz, 1H), 2.29 (dd, J = 6.4, 2.3 Hz, 2H), 2.34 (s, 3H), 2.48 (dd, J = 13.5, 9.8 Hz, 1H), 3.83 
(ddd, J = 6.9, 6.9, 5.0 Hz, 1H), 3.88 (s, 3H), 3.90 (ddd, J = 6.9, 6.9, 6.9 Hz, 1H), 4.03 (ddd, J = 6.9, 6.9, 6.9 
Hz, 1H), 4.22 (ddd, J = 6.9, 6.9, 5.0 Hz, 1H), 4.62 (s, 1H), 5.68 (d, J = 9.6 Hz, 1H), 6.24 (d, J = 9.2 Hz, 1H), 
6.61 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 3.8, 4.2, 8.4, 27.2, 33.2, 35.3, 41.6, 52.1, 52.6, 56.3, 62.3, 64.9, 66.5, 
72.6, 96.4, 108.6, 112.6, 117.3, 122.3, 123.5, 131.0, 139.7, 144.0, 146.0. 
HR-MS (ESI): m/z [M+H]+ calcd for C24H32NO5: 414.2281. Found: 414.2263. 
Elemental Analysis: Anal Calcd for C24H32NO5·0.18CHCl3: C, 68.98; H, 7.94; N, 3.33, Found: C, 69.33; H, 
7.58; N, 3.46. 
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(3aR,3a1S,9aR)-3a1-{2-[(Cyclopropylmethyl)(methyl)amino]ethyl}-5-methoxy-1,2,3a,3a1-tetrahydro-9aH-
spiro[phenanthro[4,5-bcd]furan-3,2′-[1,3]dioxolan]-9a-yl acetate (60) 
 
 
 
 
 
A solution of compound 59 (49.7 mg, 0.120 mmol) in Ac2O (2.0 mL, 21.2 mmol) was stirred at 100 °C for 
3 h, then cooled to room temperature, and concentrated under reduced pressure. The crude product was purified 
by PLC [n-hexane/EtOAc/MeOH/NH3 aq. = 50/100/9/1] to afford acetate 60 (54.4 mg, 99%) as a brown oil. 
 
IR (neat): 1732, 1506 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) (–0.07)–0.08 (m, 2H), 0.35–0.49 (m, 2H), 0.67–0.79 (m, 1H), 1.39–1.52 
(m, 1H), 1.59–1.71 (m, 2H), 1.94 (ddd, J = 12.5, 12.5, 4,4 Hz, 1H), 2.06–2.27 (m, 4H), 2.10 (s, 3H), 2.20 (s, 
3H), 2.47 (ddd, J = 12.5, 12.5, 4.4 Hz, 1H), 2.81–2.93 (m, 1H), 3.85 (ddd, J = 6.4, 6.4, 5.0 Hz, 1H), 3.89 (s, 
3H), 3.91 (ddd, J = 6.9, 6.4, 6.4 Hz, 1H), 4.07 (ddd, J = 6.9, 6.4, 6.4 Hz, 1H), 4.23 (ddd, J = 6.9, 6.9, 5.0 Hz, 
1H), 4.73 (s, 1H), 6.30 (d, J = 9.8 Hz, 1H), 6.44 (d, J = 9.8 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 8.2 
Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 3.7, 3.8, 8.7, 22.4, 27.0, 27.4, 32.5, 42.4, 51.6, 53.0, 56.3, 62.7, 65.0, 
66.6, 87.0, 95.4, 107.9, 112.9, 117.9, 122.4, 124.3, 127.9, 128.9, 144.1, 146.2, 170.1. 
HR-MS (ESI): m/z [M+H]+ calcd for C26H34NO6: 456.2386. Found: 456.2376. 
  
52 
 
 (4aR,10aR)-4a-[2-(Dimethylamino)ethyl]-6-methoxy-1,2,4,4a-tetrahydro-10aH-spiro[phenanthrene-3,2′-
[1,3]dioxolan]-10a-ol (63) 
 
 
 
 
A mixture of compound 62 (0.656 g, 1.90 mmol) and MeI (3.0 mL, 48.2 mmol) in DMF (3.0 mL) was stirred 
at 80 °C in a sealed tube for 16 h. The reaction mixture was cooled to room temperature, and concentrated 
under reduced pressure. The crude residue was dissolved in 1,4-dioxane (10 mL), and 1 M aqueous NaOH 
solution (10 mL, 10.0 mmol) was added. The mixture was stirred for 4 h at 80 °C, then cooled to room 
temperature, and was extracted with CHCl3 (30, 20, and 10 mL). The organic layer was dried over Na2SO4, 
and concentrated under reduced pressure. The crude product was purified by column chromatography on silica 
gel (0→10% (NH3 aq./MeOH = 1/9) in CHCl3) to afford compound 63 (413 mg, 60%) as a colorless solid.  
 
mp 121.5–122.3 °C. 
IR (KBr): 1607, 1487, 1277 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.33–1.74 (m, 4H), 1.92–2.12 (m, 4H), 2.17–2.35 (m, 1H), 2.23 (s, 6H), 
2.54 (dd, J = 12.1, 12.1 Hz, 1H), 3.80 (s, 3H), 3.84–4.02 (m, 4H), 5.77 (d, J = 9.6 Hz, 1H), 6.31 (d, J = 9.6 Hz, 
1H), 6.68 (dd, J = 8.2, 2.8 Hz, 1H), 6.93 (d, J = 2.8 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H). One proton (OH) was 
not observed. 
13C NMR (100 MHz, CDCl3): δ (ppm) 30.4, 32.6, 36.5, 37.1, 44.2 (two carbons), 47.9, 54.3, 55.2, 63.8, 64.3, 
71.1, 109.4, 110.1, 113.2, 125.0, 125.4, 128.1, 135.7, 144.7, 158.3. 
HR-MS (ESI): m/z [M+H]+ calcd for C21H30NO4: 360.2175. Found: 360.2176. 
Elemental Analysis: Anal Calcd for C21H30NO4·0.5H2O: C, 68.45; H, 8.21; N, 3.80, Found: C, 68.28; H, 7.86; 
N, 4.03. 
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Retro-ene reaction of compound 63 via 64 
 
 
 
 
 
A mixture of compound 63 (31.3 mg, 0.090 mmol) in Ac2O (2.00 mL, 21.2 mmol) was stirred at 60 °C for 
4 h, then cooled to room temperature, and concentrated under reduced pressure to afford 64 as a crude product. 
 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.33 (d, J = 14.7 Hz, 1H), 1.58 (ddd, J = 13.8, 13.8, 3.4 Hz, 1H), 1.79 
(ddd, J = 13.2, 6.5, 3.3 Hz, 1H), 1.86 (dd, J = 14.7, 3.2 Hz, 1H), 1.92 (s, 3H), 2.10 (ddd, J = 12.8, 3.4, 3.4 Hz, 
1H), 2.31 (ddd, J = 13.4, 13.4, 3.4 Hz, 1H), 2.71 (s, 3H), 2.78 (ddd, J = 14.7, 9.2, 7.3 Hz, 1H), 3.10 (s, 3H), 
3.24 (ddd, J = 14.2, 10.5, 5.0 Hz, 1H), 3.66–3.86 (m, 4H), 3.78 (s, 3H), 3.86–4.00 (m, 2H), 5.55 (d, J = 9.6 Hz, 
1H), 6.70 (dd, J = 8.2, 2.3 Hz, 1H), 6.77 (d, J = 2.3 Hz, 1H), 7.07 (d, J = 9.6 Hz, 1H), 7.11 (d, J = 8.2 Hz, 1H). 
 
The crude product 64 was dissolved in Ac2O (2.0 mL, 21.2 mmol), and stirred under reflux for 2 h. The 
mixture was cooled to room temperature, and concentrated under reduced pressure. The crude product was 
purified by PLC (n-hexane:THF = 2:3) to afford compound 56 (26.3 mg, 81%). 
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(4b′R,8a′S,9′R)-3′-Methoxy-11′-(methyl-d3)-7′,8′,9′,10′-tetrahydro-5′H,8a′H-spiro[[1,3]dioxolane-2,6′-
[9,4b](epiminoethano)phenanthren]-8a′-ol (70) 
 
 
 
 
To a suspension of LiAlD4 (536 mg, 12.8 mmol) in THF (6.0 mL) was added a solution of 61 (703 mg, 1.28 
mmol) in THF (6.0 mL) at 0 °C, and the mixture was stirred at room temperature for 1 h. The reaction was 
quenched with saturated aqueous potassium sodium tartrate solution (30 mL), and the mixture was extracted 
with CHCl3 (30, 20, and 10 mL). The organic layer was dried over Na2SO4, and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel (0→10% (NH3 aq./MeOH 
= 1/9] in CHCl3} to afford compound 70 (331 mg, 74%) as a colorless solid. 
 
mp 172.3–174.1 °C. 
IR (KBr): 3418, 2243, 1614, 1497, 1270 cm-1. 
1H NMR (400 MHz, C6D6): δ (ppm) 0.89–1.00 (m, 1H), 1.54 (ddd, J = 12.4, 4.1, 2.3 Hz, 1H), 1.68–1.77 (m, 
1H), 1.89–2.03 (m, 4H), 2.34 (dd, J = 14.2, 2.3 Hz, 1H), 2.41–2.50 (m, 2H), 2.51 (dd, J = 17.9, 5.5 Hz, 1H), 
2.71 (ddd, J = 13.7, 12.8, 4.6 Hz, 1H), 2.80 (d, J = 17.9 Hz, 1H), 3.33–3.42 (m, 1H), 3.45 (s, 3H), 3.47–3.55 
(m, 2H), 3.56–3.63 (m, 1H), 6.69 (dd, J = 8.2, 2.8 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 7.02 (d, J = 2.8 Hz, 1H). 
13C NMR (100 MHz, C6D6): δ (ppm) 24.2, 30.5, 31.4, 37.8, 38.4, 41.5 (sept, J = 20.6 Hz), 42.1, 45.7, 54.8, 
63.1, 63.7, 64.3, 68.9, 109.4, 111.7, 113.0, 127.4, 127.9, 142.7, 158.0. 
HR-MS (ESI): m/z [M+H]+ calcd for C20H25D3NO4: 349.2207. Found: 349.2205. 
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(4aR,10aR)-4a-{2-[Bis(methyl-d3)amino]ethyl}-6-methoxy1,2,4,4a-tetrahydro-10aH-spiro[phenanthrene-
3,2'-[1,3]dioxolan]-10a-ol (69) 
 
 
 
 
 
A mixture of 70 (0.308 g, 0.880 mmol) and CD3I (2.0 mL, 31.5 mmol) in DMF (2.0 mL) was stirred at 80 °C 
in a sealed tube for 14 h. The reaction mixture was cooled to room temperature, and concentrated under reduced 
pressure. The crude residue was dissolved in 1,4-dioxane (6.0 mL), and 1 M aqueous NaOH solution (6.0 mL, 
6.00 mmol) was added. The mixture was stirred at 80 °C for 6 h, then cooled to room temperature, and extracted 
with CHCl3 (40, 20, and 10 mL). The organic layer was dried over Na2SO4, and concentrated under reduced 
pressure. The residue was purified by column chromatography on silica gel (0→10% (NH3 aq./MeOH = 1/9] 
in CHCl3) to afford compound 69 (172 mg, 53%) as a colorless oil. 
 
IR (neat): 3367, 2192, 2048, 1606, 1489, 1276 cm-1. 
1H NMR (400 MHz, CDCl3): δ (ppm) 1.32–1.73 (m, 4H), 1.94–2.13 (m, 3H), 1.96 (ddd, J = 15.8, 11.5, 1.4 Hz, 
1H), 2.25 (d, J = 14.2 Hz, 1H), 2.52 (ddd, J = 12.8, 11.9, 0.9 Hz, 1H), 3.79 (s, 3H), 3.82–4.00 (m, 4H), 5.76 
(d, J = 9.6 Hz, 1H), 6.30 (d, J = 9.6 Hz, 1H), 6.67 (dd, J = 8.2, 2.8 Hz, 1H), 6.92 (d, J = 2.8 Hz, 1H), 6.98 (d, 
J = 8.2 Hz, 1H). 
13C NMR (100 MHz, CDCl3): δ (ppm) 30.3, 32.5, 36.5, 37.0, 43.2 (sept, J = 19.7 Hz, ×2), 47.9, 54.1, 55.1, 
63.7, 64.3, 71.0, 109.3, 110.0, 113.2, 124.9, 125.4, 128.1, 135.7, 144.7, 158.3. 
HR-MS (ESI): m/z [M+H]+ calcd for C21H24D6NO4: 366.2551. Found: 366.2543. 
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N-{2-[(4aS)-6-Methoxy-1,9-dihydro-2H-spiro[phenanthrene-3,2′-[1,3]dioxolan]-4a(4H)-yl-9-d]ethyl}-N-
(methyl-d3)acetamide (71) 
 
 
 
 
 
A solution of 69 (49.1 mg, 0.130 mmol) in Ac2O (2.0 mL, 21.2 mmol) was stirred under reflux for 4 h, then 
cooled to room temperature, and concentrated under reduced pressure. The crude residue was purified by PLC 
(CH2Cl2:MeOH = 3:1) to afford compound 71 (25.0 mg, 50%) as a colorless oil. 
 
IR (neat): 2278, 2074, 1644, 1504, 1274 cm-1. 
1H NMR (400 MHz, C6D6, mixture of rotamers): δ (ppm) 1.54 (s, 1.2H), 1.51–1.76 (m, 1.4H), 1.66 (s, 1.8H), 
1.78–1.91 (m, 1H), 1.91–2.13 (m, 2H), 2.07 (ddd, J = 13.7, 4.6, 2.8 Hz, 0.4H ), 2.36 (dd, J = 13.7, 2.3 Hz, 
0.6H), 2.42–2.58 (m, 2H), 2.65–2.76 (m, 0.6H), 2.81–3.08 (m, 1.4H), 3.07–3.18 (m, 1H), 3.25–3.72 (m, 4.6H), 
3.33 (s, 1.8H), 3.41 (s, 1.2H), 5.53 (dd, J = 4.6 1.4 Hz, 0.6H), 5.63 (dd, J = 4.6 1.4 Hz, 0.4H), 6.66–6.76 (m, 
1H), 6.81–6.91 (m, 1.6H), 7.06 (d, J = 2.3 Hz, 0.4H). 
13C NMR (100 MHz, C6D6, mixture of rotamers): δ (ppm) 20.6, 21.5, 29.1 (t, J = 19.2 Hz), 29.2 (t, J = 19.2 
Hz), 30.3, 30.4, 32.2 (sept, J = 21.1 Hz), 34.5 (sept, J = 21.1 Hz), 36.2, 36.3, 36.8, 38.1, 41.5, 41.8, 44.4, 47.1, 
48.6, 49.3, 54.8, 63.6, 63.8, 64.9, 64.91, 109.0, 109.3, 110.5, 110.9, 112.4, 112.7, 120.4, 120.6, 125.2, 125.6, 
129.2, 136.5, 137.2, 142.6, 143.1, 159.1, 159.2, 168.8, 168.9. 
HR-MS (ESI): m/z [M+Na]+ calcd for C22H25D4NO4Na: 398.2245. Found: 398.2259. 
 
  
57 
 
Table 1. Crystal data and structure refinement for compound 49 
 
Compound 49 
CCDC number 1493066 
Molecular formula C17H21NO3 
Formula weight 287.36 
Temperature (K) 93 
Wavelength (Å) 1.54187 
Crystal size (mm3) 0.232 × 0.225 × 0.170 
Crystal system 
Space group 
Unit cell dimensions 
a/b/c (Å) 
α/β/γ (°) 
Volume (Å) 
Z 
Density (calculated) (g/cm3) 
F (000) 
Index ranges 
Reflections collected 
Independent reflections 
R (int) 
Completeness to theta 
Refinement method 
No. Observations (All reflections) 
No. Variables 
Reflection/Parameter Ratio 
Residuals: R1 [I > 2.00 σ (I)] 
Residuals: R (All reflections) 
Residuals: wR2 (All reflections) 
Goodness-of-fit 
Absolute structure parameter 
Max. and min. peak in Final Diff. Map (e-/Å3) 
orthorhombic 
P212121 
 
6.25838(14)/14.0249(3)/16.6165(4) 
90/90/90 
1458.48(6) 
4 
1.309 
616.00 
–7<=h<=7, –16<=k<=16, –20<=l<=19 
15886 
2667 
0.0266 
67.687 °, 100% 
Full-matrix least-squares on F2 
2667 
191 
13.96 
0.0286 
0.0293 
0.0759 
1.042 
0.08 (4) 
–0.19 / 0.23 
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